(Q84512666)
Statements
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06) (English)
Swiss Group for Clinical Cancer Research (SAKK)
C Rochlitz
T Ruhstaller
S Lerch
C Spirig
J Huober
T Suter
M Bühlmann
M Fehr
A Schönenberger
R von Moos
R Winterhalder
D Rauch
A Müller
M Mannhart-Harms
R Herrmann
B Cliffe
M Mayer